A new analysis of data from the SELECT trial shows that semaglutide, a GLP-1 receptor agonist, provides a clear cardiovascular protective effect in people with overweight or obesity and already established cardiovascular disease, even when they do not have diabetes
This is one of the cleaner marks to hit because 75 falls on a visible graduation line on most quality syringes
Ozempic is the brand name for semaglutide, and according to Gervacio, its the most popular choice since it has shown the most promise for weight loss
To manage progress, address potent side effects, and adjust dosage according to tolerance all these things should be discussed with healthcare professionals in follow-up appointments
This includes fat loss, muscle loss, and possibly bone density